Quadrise Fuels plc (LON:QFI) – bioMSAR™ is on track to revolutionise engine fuels with low emissions, minimal risk and increased efficiency. Quadrise Fuels International plc (LON:QFI) is the global innovator..
Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the results from the COVID-19 characterisation study, the next phase of the..
Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world’s first COVID-19 characterisation study. Cathal explains what these results mean for Open Orphan,..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announced today the..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announced today that hVIVO, a..
Open Orphan (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, its subsidiary,..
Open Orphan plc (LON:ORPH) a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has noted the announcement..
Open Orphan plc (LON:ORPH) announced today that data from the first-in-human Phase I clinical study evaluating the safety, immunogenicity, and in vitro efficacy of AGS-v PLUS, Imutex Limited’s mosquito saliva..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that Venn Life Sciences, a subsidiary..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announced today the appointment of..
Cathal Friel CEO at Open Orphan plc (LON:ORPH) and Chairman of Poolbeg Pharma plc (LON:POLB) told DirectorsTalk, “As an exciting step in our AI data analysis programme, Poolbeg Pharma plc..
Shares in Oncimmune Holdings with ticker code: LON:ONC has climbed 3.51% or 6.05 points during the course of today’s session so far. Investors seem confident during this period. Range high..
Open Orphan plc (LON:ORPH), a rapidly growing specialist clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announced today its unaudited..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announced that its interim results..
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has noted the..
Open Orphan plc (LON:ORPH) today announced a £8.1m Asthma Human Challenge Study Contract Win, we caught up with CEO Cathal Friel for a few comments, who told us: We are..
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary..
